PRLD Stock Price, Prelude Therapeutics orporated Quote, Chart

Market Summary

USD3.99+0.26

Market Closed

6.97%

PRLD Stock Price

View Fullscreen

PRLD RSI Chart

PRLD Valuation

Market Cap

219.1M

Price/Earnings (Trailing)

-1.8

Price/Free Cashflow

-1.98

PRLD Price/Earnings (Trailing)

PRLD Profitability

Return on Equity

-51.39%

Return on Assets

-43.88%

Free Cashflow Yield

-50.46%

PRLD Fundamentals

PRLD Earnings

Earnings (TTM)

-121.8M

Earnings Growth (Yr)

-15.48%

Earnings Growth (Qtr)

-8.06%

Breaking Down PRLD Revenue

Last 7 days

-1.2%

Last 30 days

-13.6%

Last 90 days

30.8%

Trailing 12 Months

-37.3%

How does PRLD drawdown profile look like?

PRLD Financial Health

Current Ratio

10.79

PRLD Investor Care

Shares Dilution (1Y)

15.94%

Diluted EPS (TTM)

-2.03

Tracking the Latest Insider Buys and Sells of Prelude Therapeutics Incorporated

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 04, 2024	huang jane	sold (taxes)	-15,864	4.74	-3,347	president, cmo
Apr 04, 2024	huang jane	acquired	-	-	9,375	president, cmo
Jan 04, 2024	huang jane	sold (taxes)	-14,491	3.77	-3,844	president, cmo
Jan 04, 2024	huang jane	acquired	-	-	9,375	president, cmo
Oct 04, 2023	huang jane	acquired	-	-	9,375	president, cmo
Jul 04, 2023	huang jane	acquired	-	-	9,375	president, cmo
Jul 04, 2023	huang jane	sold (taxes)	-15,075	4.65	-3,242	president, cmo
May 25, 2023	vaddi krishna	bought	4,779	5.31	900	ceo
May 24, 2023	vaddi krishna	bought	5,011	5.0114	1,000	ceo
May 24, 2023	lim bryant david	bought	12,936	5.39	2,400	chief legal officer, corp sec.

Which funds bought or sold PRLD recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 01, 2024	CONCOURSE FINANCIAL GROUP SECURITIES, INC.	sold off	-	-	-	-%
Apr 30, 2024	Avior Wealth Management, LLC	new	-	4.00	4.00	-%
Apr 29, 2024	HighMark Wealth Management LLC	unchanged	-	23.00	237	-%
Apr 25, 2024	SIMPLEX TRADING, LLC	sold off	-100	-	-	-%
Apr 25, 2024	Bank of New York Mellon Corp	reduced	-20.81	-26,140	189,922	-%
Apr 23, 2024	AMALGAMATED BANK	reduced	-61.34	-2,000	2,000	-%
Apr 15, 2024	EXCHANGE TRADED CONCEPTS, LLC	added	44.91	114,573	302,824	0.01%
Apr 05, 2024	CWM, LLC	new	-	-	-	-%
Mar 11, 2024	VANGUARD GROUP INC	added	3.42	1,290,830	4,299,280	-%
Mar 01, 2024	GOLDMAN SACHS GROUP INC	added	105	384,076	593,232	-%

Are Funds Buying or Selling PRLD?

Are funds buying PRLD calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own PRLD

No. of Funds

Unveiling Prelude Therapeutics Incorporated's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 13, 2024	ubs asset management americas inc	0%	0	SC 13G/A
Feb 12, 2024	vaddi krishna	11.1%	4,908,086	SC 13G/A
Feb 12, 2024	flynn james e	9.85%	4,133,000	SC 13G/A
Jan 10, 2024	fmr llc	-	0	SC 13G/A
Dec 13, 2023	baker bros. advisors lp	24.3%	10,222,968	SC 13D/A
Nov 13, 2023	flynn james e	7.68%	3,222,690	SC 13G
May 24, 2023	baker bros. advisors lp	19.5%	10,219,080	SC 13D/A
May 24, 2023	orbimed advisors llc	28.6%	15,716,642	SC 13D/A
Feb 13, 2023	ubs asset management americas inc	5.24%	2,507,992	SC 13G
Feb 10, 2023	fmr llc	-	0	SC 13G/A

Recent SEC filings of Prelude Therapeutics Incorporated

View All Filings

Date Filed	Form Type	Document
Apr 26, 2024	ARS	ARS
Apr 26, 2024	DEF 14A	DEF 14A
Apr 26, 2024	DEFA14A	DEFA14A
Apr 10, 2024	8-K	Current Report
Apr 08, 2024	4	Insider Trading
Mar 04, 2024	4	Insider Trading
Mar 04, 2024	4	Insider Trading
Mar 04, 2024	4	Insider Trading
Mar 04, 2024	4	Insider Trading
Mar 04, 2024	4	Insider Trading

Peers (Alternatives to Prelude Therapeutics Incorporated)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	48.1B	6.8B	21.21%	-3.50%	-8.06	7.03	-64.45%	-224.75%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	19.0B	2.0B	-0.48%	-24.66%	-57.25	9.49	75.20%	68.82%
BMRN	15.9B	2.5B	-3.50%	-10.49%	77.41	6.43	13.74%	186.89%
INCY	11.9B	3.8B	-4.91%	-21.97%	15.99	3.16	8.58%	129.81%
MID-CAP
APLS	5.7B	396.6M	-14.74%	-44.14%	-10.83	14.44	425.83%	18.94%
BBIO	5.2B	107.9M	-3.68%	92.64%	-9.5	48.09	54.84%	-28.31%
AXSM	3.5B	270.6M	-0.50%	3.10%	-14.69	12.99	440.80%	-27.84%
ARWR	3.0B	240.7M	-7.87%	-39.98%	-10.07	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-5.69%	-19.43%	-45.92	3.87	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-1.57%	-9.52%	24.79	4.45	85.90%	-14.05%
NVAX	659.2M	983.7M	3.97%	-34.13%	-1.21	0.67	-50.36%	17.16%
CRBP	400.8M	881.7K	1.98%	349.41%	-8.99	466.16	-77.61%	-5.33%
INO	280.7M	4.9M	-3.22%	25.10%	-2.08	57.68	-54.97%	51.71%
IBIO	7.0M	2.1M	-29.72%	84.40%	-0.26	2.14	-13.45%	66.37%

Prelude Therapeutics Incorporated News

Latest updates

Prelude Therapeutics Incorporated Earnings Report: Key Takeaways & Analysis

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																		(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2018Q4
Assets	7.4%	278	259	281	198	221	242	259	281	305	331	350	370	224	240	167	94.00	22.00	16.00
Current Assets	0.3%	236	235	260	175	204	227	249	270	295	326	345	365	221	238	-	-	20.00	16.00
Cash Equivalents	59.1%	25.00	16.00	26.00	18.00	31.00	52.00	51.00	52.00	32.00	61.00	343	363	218	235	-	-	19.00	16.00
Net PPE	10.7%	7.00	7.00	6.00	5.00	5.00	5.00	4.00	4.00	4.00	3.00	3.00	3.00	2.00	2.00	-	-	2.00	1.00
Liabilities	100.3%	41.00	20.00	19.00	23.00	25.00	25.00	18.00	19.00	19.00	20.00	15.00	13.00	11.00	11.00	9.00	7.00	5.00	3.00
Current Liabilities	29.2%	22.00	17.00	15.00	20.00	22.00	22.00	16.00	16.00	19.00	20.00	15.00	12.00	11.00	11.00	-	-	5.00	2.00
Shareholder's Equity	-0.5%	237	238	262	175	195	217	241	262	286	311	334	357	212	228	-	-	-	-
Retained Earnings	-7.8%	-456	-423	-392	-362	-334	-305	-275	-248	-219	-186	-155	-128	-107	-88.18	-	-	-50.50	-22.93
Additional Paid-In Capital	4.7%	693	662	655	538	532	526	519	513	506	498	490	485	320	316	-	-	1.00	0.00
Shares Outstanding	5.4%	60.00	57.00	52.00	48.00	47.00	47.00	47.00	47.00	46.00	46.00	46.00	45.00	-	-	-	-	-	-
Float	-	-	-	77.00	-	-	-	65.00	-	-	-	343	-	-	-	-	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																			(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2018Q4
Cashflow From Operations	8.2%	-23,578	-25,683	-27,668	-30,134	-22,927	-20,439	-18,468	-21,895	-25,702	-21,774	-19,912	-16,143	-14,847	-12,507	-8,902	-9,921	-	-	-
Share Based Compensation	-12.0%	5,912	6,715	6,733	6,256	5,845	6,442	6,028	6,829	4,468	7,033	4,237	6,500	3,122	1,472	627	362	-	297	-
Cashflow From Investing	-48.6%	7,736	15,045	-75,426	17,999	1,355	21,607	58,576	153	-1,804	-260,632	-381	-986	-329	-170	-42.00	-80.00	-	-	-
Cashflow From Financing	28578.4%	25,237	88.00	111,339	-269	155	148	-41,036	41,548	1,954	711	422	161,810	-1,307	217,753	-65.00	29,847	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

PRLD Income Statement

2023-12-31

STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Operating expenses:
Research and development	$ 103,393	$ 92,889
General and administrative	28,884	30,651
Total operating expenses	132,277	123,540
Loss from operations	(132,277)	(123,540)
Other income, net	10,445	8,102
Net loss	$ (121,832)	$ (115,438)
Per share information:
Net loss per share of common stock, basic	$ (2.02)	$ (2.44)
Net loss per share of common stock, diluted	$ (2.02)	$ (2.44)
Weighted average common shares outstanding, basic	60,357,052	47,371,589
Weighted average common shares outstanding diluted	60,357,052	47,371,589
Comprehensive loss
Net loss	$ (121,832)	$ (115,438)
Unrealized gain (loss) on marketable securities, net of tax	1,915	(981)
Comprehensive loss	$ (119,917)	$ (116,419)

PRLD Balance Sheet

2023-12-31

BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 25,291	$ 30,605
Marketable securities	207,644	171,123
Prepaid expenses and other current assets	2,654	2,652
Total current assets	235,589	204,380
Restricted cash	4,044	4,044
Property and equipment, net	7,325	4,908
Right-of-use asset	30,412	1,792
Prepaid expenses and other non-current assets	295	5,376
Total assets	277,665	220,500
Current liabilities:
Accounts payable	4,580	6,777
Accrued expenses and other current liabilities	15,768	13,093
Operating lease liability	1,481	1,832
Total current liabilities	21,829	21,702
Other liabilities	3,339	3,361
Operating lease liability	15,407
Total liabilities	40,575	25,063
Commitments (note 8)
Stockholders’ equity:
Additional paid-in capital	693,252	531,682
Accumulated other comprehensive income (loss)	223	(1,692)
Accumulated deficit	(456,390)	(334,558)
Total stockholders’ equity	237,090	195,437
Total liabilities and stockholders’ equity	277,665	220,500
Voting Common Stock
Stockholders’ equity:
Common stock	4	4
Non-voting Common Stock
Stockholders’ equity:
Common stock	$ 1	$ 1

About Prelude Therapeutics Incorporated

Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT811, which is in Phase 1 clinical trials in solid tumors, including glioblastoma. The company is also developing PRT1419, a myeloid cell leukemia-1 inhibitor, which is in Phase 1 clinical trial for the treatment of selected relapsed/refractory myeloid or B-cell malignancies; PRT2527, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; PRT3645, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 2 clinical trial for the treatment of advanced and metastatic solid tumors; and PRT3879, a SMARCA2 selective protein degrader, which is in Phase 1 clinical trial for the treatment of advanced and metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion. The company was incorporated in 2016 and is headquartered in Wilmington, Delaware.

CEO	Dr. Krishna Vaddi D.V.M., Ph.D.
WEBSITE	https://preludetx.com
INDUSTRY	Biotechnology
EMPLOYEES	122

Prelude Therapeutics Incorporated Frequently Asked Questions

What is the ticker symbol for Prelude Therapeutics Incorporated? What does PRLD stand for in stocks?

PRLD is the stock ticker symbol of Prelude Therapeutics Incorporated. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Prelude Therapeutics Incorporated (PRLD)?

As of Thu May 02 2024, market cap of Prelude Therapeutics Incorporated is 219.13 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of PRLD stock?

You can check PRLD's fair value in chart for subscribers.

What is the fair value of PRLD stock?

You can check PRLD's fair value in chart for subscribers. The fair value of Prelude Therapeutics Incorporated is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Prelude Therapeutics Incorporated is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for PRLD so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Prelude Therapeutics Incorporated a good stock to buy?

The fair value guage provides a quick view whether PRLD is over valued or under valued. Whether Prelude Therapeutics Incorporated is cheap or expensive depends on the assumptions which impact Prelude Therapeutics Incorporated's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for PRLD.